We use cookies to improve your experience. See our Privacy Policy.
On November 6, 2026 CG Oncology, Inc. submitted a Form 8‑K to the SEC. The report contains Item 2.02, which provides the company's most recent results of operations and financial condition, and Item 9.01, which attaches the complete set of financial statements as Exhibit 99.1. While the filing itself does not disclose the specific numbers in the excerpt provided, investors should review the attached financial statements for revenue, earnings per share, cash flow, and any changes from prior periods. No insider trades or new compensation arrangements were reported in this filing, and no explicit risk factors were highlighted, though the performance results could materially affect the share price.
A Form 8‑K is a current report that companies must file to disclose material events. For CG Oncology, the filing signals that the company is providing its latest financial results, which can cause short‑term price movement.
The numbers are in the financial statements attached as Exhibit 99.1. Download the exhibit from the SEC EDGAR page for accession number 0001991792-26-000011.
If the results differ significantly from analyst expectations—either better or worse—the stock could react sharply. Review the disclosed figures and compare them to consensus estimates before deciding.